Similarly, the role of immunotherapy has also regained momentum with the recognition that checkpoint inhibition can lead to survival improvement as demonstrated with the use of the PD1 inhibitor nivolumab in the second-line RCC setting (9). Here, PDCD1 is linked to renal cell adenocarcinoma.